The global hunter syndrome treatment market is estimated to witness significant growth during the forecast period. Innovative novel therapies in clinical trials and increasing R&D activities by major market players for the development of hunter syndrome treatment are the major two driving factors that are propelling the global hunter syndrome treatment market.
A full report of Hunter Syndrome Treatment Market is available at: https://www.omrglobal.com/industry-reports/hunter-syndrome-treatment-market
Few Recent Innovations In The Market-
- In December 2019, Regenxbio’s R&D on gene therapy RGX-121 showed a positive action in the hunter syndrome treatment study. In this study, the company found this gene therapy can decline high levels of heparan sulfate which are associated with neurocognitive by 33% from baseline to week 8. Also, this study found that those patients who progressed beyond week 24 showed stable neurocognitive development. The estimated completion date of this R&D study is December 2022.
- In November 2019, Bioasis announced the allowance of patent applications of xB3 platform in Japan, later in 2020, it allowed patent applications in the US and Europe.
- In June 2019, Denali Therapeutics got approval from the US FDA for DNL310, it is an enzyme replacement therapy for patients with Hunter syndrome.
- In August 2018, ArmaGen received the US Orphan Drug Designation for AGT-184. It is an investigational enzyme replacement therapy (ERT) for the treatment of hunter syndrome treatment. In December 2019, Regenxbio’s R&D on gene therapy RGX-121 showed a positive action in the hunter syndrome treatment study. In this study, the company found this gene therapy can decline high levels of heparan sulfate which are associated with neurocognitive by 33% from baseline to week 8. Also, this study found that those patients who progressed beyond week 24 showed stable neurocognitive development. The estimated completion date of this R&D study is December 2022.
- In February 2018, Inventive announced it shows a positive outcome of biomarker study measuring intracellular GAGs in leukocytes from MPS VI patients. This R&D is intended to reduce leukoGAGs enzymes using MPS VI and limited ERT.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/hunter-syndrome-treatment-market
Global Hunter Syndrome Treatment Market Segmentation
By Treatment
- Enzyme Replacement Therapy (ERT)
- Hematopoietic Stem Cell Transplant (HSCT)
- Others ( Gene Therapy, Bone Marrow Transplant, Tonsillectomy)
